87552 Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, quantification

Name of the Procedure:

Infectious Agent Detection by Nucleic Acid (DNA or RNA); Mycobacteria Species, Quantification

Summary

This procedure detects and measures the amount of Mycobacteria DNA or RNA in a patient's sample. It uses advanced molecular techniques to identify the presence of these bacteria, which can cause serious infections such as tuberculosis.

Purpose

The procedure is used to diagnose infections caused by Mycobacteria, detect the presence of the bacteria in various stages of infection, and monitor the effectiveness of treatment. The goal is to quickly and accurately identify the bacterial load, which aids in proper disease management.

Indications

• Persistent cough, fever, and weight loss
• Symptoms of pulmonary tuberculosis
• Known or suspected exposure to Mycobacteria
• Monitoring response to anti-mycobacterial therapy

Preparation

• No special preparations are usually needed.
• Patients may be instructed to provide a sputum sample or other type of body fluid/sample.
• Any prior antibiotic use should be reported to the healthcare provider.

Procedure Description

1. A sample (e.g., sputum, blood, or tissue) is collected from the patient.
2. The sample is processed in a specialized laboratory.
3. DNA or RNA is extracted from the sample.
4. Polymerase Chain Reaction (PCR) or other nucleic acid amplification techniques are employed to detect and quantify the Mycobacteria genetic material.
5. Results are analyzed to determine the presence and quantity of Mycobacteria.

• Tools: PCR machine, nucleic acid extraction kits.
• No anesthesia or sedation is required as it is a non-invasive test.

Duration

The entire process from sample collection to results typically takes 1-3 days, although this can vary based on the laboratory.

Setting

The procedure is conducted in a clinical laboratory setting, which can be part of a hospital or specialized diagnostic center.

Personnel

• Medical Laboratory Technicians or Technologists
• Pathologists
• Infectious Disease Specialists, if required

Risks and Complications

• Minimal risk of contamination or false positive/negative results.
• Rare procedural complications related to sample collection (e.g., discomfort during sputum collection).

Benefits

• Accurate and rapid detection of Mycobacteria.
• Timely results allow for prompt treatment decisions.
• Helps in monitoring the efficacy of therapeutic interventions.

Recovery

• No recovery time is required as this is a diagnostic test.
• Patients can resume normal activities immediately after submitting a sample.
• Follow-up appointments may be necessary based on test results.

Alternatives

• Culture methods: Slow and can take several weeks but considered a gold standard.
• Chest X-rays: Useful for pulmonary TB but not definitive.
• Tuberculin Skin Test (TST) or Interferon-Gamma Release Assay (IGRA): Indirect methods, not specific for active infection.

Patient Experience

• Sample collection is generally quick and painless, though the type of sample may vary.
• There may be mild discomfort depending on the sample type.
• Patients should not feel significant pain or side effects from the procedure.